metiamide has been researched along with Duodenal-Diseases* in 2 studies
2 trial(s) available for metiamide and Duodenal-Diseases
Article | Year |
---|---|
Nocturnal metiamide treatment in the management of healed duodenal ulceration.
This paper presents the results of a pilot study to investigate whether the administration of a nocturnal dose of metiamide (the first orally active H2 receptor antagonist) would prevent or delay the relapse of duodenal ulceration after initial ulcer healing. Sixteen patients took part in a double-blind trial to compare metiamide (400 mg) with placebo. Endoscopically confirmed duodenal ulcer relapses occurred in two out of eight on metiamide and six out of eight on placebo. There was a significant prolongation of remission in those in those on the active drug with an apparent reduction in duodenitis. Topics: Adult; Aged; Clinical Trials as Topic; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Middle Aged; Recurrence; Remission, Spontaneous; Thiourea; Time Factors | 1977 |
Treatment of duodenal ulcer by metiamide. A multicentre trial.
In a multicentre double-blind trial 68 patients with endoscopically confirmed duodenal ulceration received metiamide (36 patients) or placebo (32 patients) for four weeks. Healing of duodenal ulcers was significantly increased in patients receiving metiamide (67%) compared with those on placebo (25%). There was also an assoicated significant decrease in daytime pain and antacid consumption in those on metiamide. Topics: Antacids; Clinical Trials as Topic; Drug Evaluation; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Pain; Thiourea | 1975 |